{"id":1366,"date":"2024-07-19T14:05:36","date_gmt":"2024-07-19T14:05:36","guid":{"rendered":"https:\/\/fhucare.com\/event\/main-achievements-significant-actions-2020-2024\/"},"modified":"2025-12-25T19:00:48","modified_gmt":"2025-12-25T18:00:48","slug":"main-achievements-significant-actions-2020-2024","status":"publish","type":"post","link":"https:\/\/fhucare.com\/fr\/event\/main-achievements-significant-actions-2020-2024\/","title":{"rendered":"MAIN ACHIEVEMENTS &amp; SIGNIFICANT ACTIONS 2020-2024"},"content":{"rendered":"<p><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"><strong>FHU CARE Cancer and Autoimmunity Relationships<br \/> <\/strong><strong>MAIN ACHIEVEMENTS &amp; SIGNIFICANT ACTIONS 2020-2024<\/strong><\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> <a href=\"fr\/research-projects\"><strong>TNF SENESCENCE clinical trial<\/strong><\/a> (TNFSEN)<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Aim: Investigate T cell senescence and exhaustion in autoimmune diseases.<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Inclusion: <strong>67<\/strong> patients (25 RA, 22 SpA, 20 Sj\u00f6gren&rsquo;s).<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Findings: Higher senescence and exhaustion in autoimmune conditions. <\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> One article under revision and one submitted.<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Lead Researchers: <strong>Pr. Ga\u00ebtane Nocturne, Pr. Nathalie Chaput-Gras<\/strong>, <strong>Dr. Samuel Bitoun.<\/strong><\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"><a href=\"fr\/research-projects\/citar\"><strong>CITAR clinical trial (Checkpoint Inhibitors Treatment Arthritis)<\/strong><\/a> <\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Aim: Compare early IL-6R blockade (tocilizumab) vs. glucocorticoids for treating arthritis from cancer immunotherapy.<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Participants: <strong>112<\/strong> patients, randomized, multicenter trial. Sponsored by <strong>Karolinska Institute<\/strong>.<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Results: First trial center opened in Sweden in March 2024. 8 out of 106 patients included so far.<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> PI for France: <strong>Dr. Samuel Bitoun<\/strong>. Scientific Coordinator: <strong>Pr. Xavier Mariette<\/strong>.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"><a href=\"fr\/research-projects\"><strong>PICASSO clinical trial<\/strong><\/a><\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Goal: Evaluate fecal transplantation combined with immunotherapy on anti-cancer efficacy in metastatic melanoma patients.<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Participants:<strong> 70<\/strong> patients.<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Status: Recruitment complete, results expected by end of 2024.<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Lead: <strong>Pr. Franck Carbonnel, Patricia Lepage<\/strong>.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"><a href=\"fr\/research-projects\"><strong>PREMIS study<\/strong><\/a><strong><br \/> <\/strong>Objective: Identify predictive biomarkers of immunological adverse events from immune checkpoint inhibitors.<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Participants: <strong>1,000 <\/strong>patients.<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Results: Multiple publications and ongoing collaborations.<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Leads: <strong>Pr. Aur\u00e9lien Marabelle, Dr. Fran\u00e7ois-Xavier Danlos<\/strong>.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"><a href=\"https:\/\/www.medecine.universite-paris-saclay.fr\/en\/spoc-miracip\"><strong>SPOC MIRACIP Online Course<\/strong><\/a><\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Content: Management of toxicities associated with anti-cancer immunotherapies.<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Outcome: Over <strong>200<\/strong> registrations across<strong> 2 <\/strong>editions, with participants from <strong>11 <\/strong>countries.<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Coordinator: <strong>Pr. Olivier Lambotte<\/strong>.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"><a href=\"https:\/\/gustaveroussy.my.site.com\/formation\/s\/formation-academique\/a0Y0900000FtwedEAB\/symposium-itox-2024?language=fr\"><strong>iTox Symposium 2024<\/strong><\/a><\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Purpose: Update on toxicities associated with anti-cancer immunotherapies, featuring international speakers, including Americans. Organized annually.<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Date: May 22-23, 2024, at Bic\u00eatre Faculty of Medicine, UPSaclay.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"><a href=\"https:\/\/enseignement.gustaveroussy.fr\/fr\/podcasts2\/oncoach2.html\"><strong>ONCOach Podcasts<\/strong><\/a><\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Content: <strong>13 <\/strong>episodes on immunotherapy toxicities, initiated by <strong>Dr. Audrey Perret<\/strong>.<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Audience: Healthcare personnel.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"><a href=\"https:\/\/www.aphp.fr\/actualite\/deuxieme-edition-de-women-science-sante-des-femmes-et-femmes-de-sante\"><strong>Women in Sciences (WiS) Workshops<\/strong><\/a><\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Events: <strong>3<\/strong> editions focusing on <strong>women&rsquo;s health and gender equality in healthcare<\/strong>, with 326 participants.<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Next Edition: November 20, 2024, at H\u00f4pital Europ\u00e9en Georges Pompidou.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"><strong>European Guidelines for the Management of Immune-related Adverse Events (irAE)<\/strong><\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Lead: <strong>Pr. Xavier Mariette<\/strong> led the development of guidelines for the diagnosis and management of rheumatic irAEs.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"><strong>MAIN SUBMITTED PROJECTS<\/strong><\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> Funding Applications: FHU CARE has applied for <strong>over 50 projects<\/strong>, securing <strong>\u20ac2.2 million<\/strong> in funding.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"><strong><a href=\"https:\/\/dim-itac.com\/en\/\">DIM ITAC<\/a><\/strong><\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> The Paris region (\u00cele-de-France) awarded <strong>Pr. Caroline Robert<\/strong> and <strong>Pr. Xavier Mariette<\/strong> a Major Interest Domain (DIM) on Immunotherapies, Auto-immunity, and Cancer with funding of <strong>\u20ac11 million<\/strong> for 5 years.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> <strong><a href=\"fr\/publications\">PUBLICATIONS<\/a> <\/strong><strong><br \/> <\/strong>Total FHU CARE Publications (2021-2024): <strong>135 entries<\/strong>. See the website<strong> <a href=\"fr\/publications\">under the Publications section<\/a><\/strong>.<\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"><strong>COMMUNICATION AND OUTREACH<\/strong><strong><br \/> <\/strong><strong>Newsletter<\/strong>: News2CARE sent monthly to <strong>over 300 contacts<\/strong>.<strong><br \/> Social media<\/strong>: Active on <a href=\"https:\/\/www.linkedin.com\/in\/fhucare\/\">LinkedIn<\/a> and <a href=\"https:\/\/x.com\/CareFhu\">Twitter<\/a>.<\/span><br \/><span style=\"font-family: arial, helvetica, sans-serif;font-size: 12pt\"> <strong>Events Organized<\/strong>: <strong>6<\/strong> General Assemblies, <strong>1 <\/strong>Webinar, <strong>3<\/strong> Scientific Workshops.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>FHU CARE Cancer and Autoimmunity Relationships MAIN ACHIEVEMENTS &amp; SIGNIFICANT ACTIONS 2020-2024 TNF SENESCENCE clinical trial (TNFSEN) Aim: Investigate T cell senescence and exhaustion in autoimmune diseases. Inclusion: 67 patients (25 RA, 22 SpA, 20 Sj\u00f6gren&rsquo;s). Findings: Higher senescence and exhaustion in autoimmune conditions. One article under revision and one submitted. Lead Researchers: Pr. Ga\u00ebtane [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1367,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"event_date":"2020-2024","event_location":"FHU CARE Mains Achievements","event_time":"","footnotes":""},"categories":[10],"tags":[],"class_list":["post-1366","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-event"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MAIN ACHIEVEMENTS &amp; SIGNIFICANT ACTIONS 2020-2024 - FHU CARE\u00b2<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fhucare.com\/fr\/event\/main-achievements-significant-actions-2020-2024\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MAIN ACHIEVEMENTS &amp; SIGNIFICANT ACTIONS 2020-2024 - FHU CARE\u00b2\" \/>\n<meta property=\"og:description\" content=\"FHU CARE Cancer and Autoimmunity Relationships MAIN ACHIEVEMENTS &amp; SIGNIFICANT ACTIONS 2020-2024 TNF SENESCENCE clinical trial (TNFSEN) Aim: Investigate T cell senescence and exhaustion in autoimmune diseases. Inclusion: 67 patients (25 RA, 22 SpA, 20 Sj\u00f6gren&rsquo;s). Findings: Higher senescence and exhaustion in autoimmune conditions. One article under revision and one submitted. Lead Researchers: Pr. Ga\u00ebtane [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fhucare.com\/fr\/event\/main-achievements-significant-actions-2020-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"FHU CARE\u00b2\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-19T14:05:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-25T18:00:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fhucare.com\/wp-content\/uploads\/2024\/07\/LOGO-H-FHU-CARE-MULTICOLOR.png\" \/>\n\t<meta property=\"og:image:width\" content=\"554\" \/>\n\t<meta property=\"og:image:height\" content=\"176\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"adm-fhuc2-la\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"adm-fhuc2-la\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/main-achievements-significant-actions-2020-2024\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/main-achievements-significant-actions-2020-2024\\\/\"},\"author\":{\"name\":\"adm-fhuc2-la\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#\\\/schema\\\/person\\\/2e9ff2878c5ffade65bdda120c97b8e0\"},\"headline\":\"MAIN ACHIEVEMENTS &amp; SIGNIFICANT ACTIONS 2020-2024\",\"datePublished\":\"2024-07-19T14:05:36+00:00\",\"dateModified\":\"2025-12-25T18:00:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/main-achievements-significant-actions-2020-2024\\\/\"},\"wordCount\":396,\"publisher\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/main-achievements-significant-actions-2020-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/LOGO-H-FHU-CARE-MULTICOLOR.png\",\"articleSection\":[\"Event\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/main-achievements-significant-actions-2020-2024\\\/\",\"url\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/main-achievements-significant-actions-2020-2024\\\/\",\"name\":\"MAIN ACHIEVEMENTS &amp; SIGNIFICANT ACTIONS 2020-2024 - FHU CARE\u00b2\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/main-achievements-significant-actions-2020-2024\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/main-achievements-significant-actions-2020-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/LOGO-H-FHU-CARE-MULTICOLOR.png\",\"datePublished\":\"2024-07-19T14:05:36+00:00\",\"dateModified\":\"2025-12-25T18:00:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/main-achievements-significant-actions-2020-2024\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/main-achievements-significant-actions-2020-2024\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/main-achievements-significant-actions-2020-2024\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/LOGO-H-FHU-CARE-MULTICOLOR.png\",\"contentUrl\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/LOGO-H-FHU-CARE-MULTICOLOR.png\",\"width\":554,\"height\":176},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/event\\\/main-achievements-significant-actions-2020-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MAIN ACHIEVEMENTS &amp; SIGNIFICANT ACTIONS 2020-2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/\",\"name\":\"FHU CARE\u00b2\",\"description\":\"Innovations in Autoimmunity, Cancer &amp; Immunotherapies\",\"publisher\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#organization\"},\"alternateName\":\"CARE2\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#organization\",\"name\":\"FHU CARE\u00b2\",\"alternateName\":\"CARE2\",\"url\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/CARE2-COULEUR.svg\",\"contentUrl\":\"https:\\\/\\\/fhucare.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/CARE2-COULEUR.svg\",\"caption\":\"FHU CARE\u00b2\"},\"image\":{\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/in\\\/fhucare\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@fhucare\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fhucare.com\\\/fr\\\/#\\\/schema\\\/person\\\/2e9ff2878c5ffade65bdda120c97b8e0\",\"name\":\"adm-fhuc2-la\",\"sameAs\":[\"https:\\\/\\\/fhucare.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MAIN ACHIEVEMENTS &amp; SIGNIFICANT ACTIONS 2020-2024 - FHU CARE\u00b2","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fhucare.com\/fr\/event\/main-achievements-significant-actions-2020-2024\/","og_locale":"fr_FR","og_type":"article","og_title":"MAIN ACHIEVEMENTS &amp; SIGNIFICANT ACTIONS 2020-2024 - FHU CARE\u00b2","og_description":"FHU CARE Cancer and Autoimmunity Relationships MAIN ACHIEVEMENTS &amp; SIGNIFICANT ACTIONS 2020-2024 TNF SENESCENCE clinical trial (TNFSEN) Aim: Investigate T cell senescence and exhaustion in autoimmune diseases. Inclusion: 67 patients (25 RA, 22 SpA, 20 Sj\u00f6gren&rsquo;s). Findings: Higher senescence and exhaustion in autoimmune conditions. One article under revision and one submitted. Lead Researchers: Pr. Ga\u00ebtane [&hellip;]","og_url":"https:\/\/fhucare.com\/fr\/event\/main-achievements-significant-actions-2020-2024\/","og_site_name":"FHU CARE\u00b2","article_published_time":"2024-07-19T14:05:36+00:00","article_modified_time":"2025-12-25T18:00:48+00:00","og_image":[{"width":554,"height":176,"url":"https:\/\/fhucare.com\/wp-content\/uploads\/2024\/07\/LOGO-H-FHU-CARE-MULTICOLOR.png","type":"image\/png"}],"author":"adm-fhuc2-la","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"adm-fhuc2-la","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fhucare.com\/fr\/event\/main-achievements-significant-actions-2020-2024\/#article","isPartOf":{"@id":"https:\/\/fhucare.com\/fr\/event\/main-achievements-significant-actions-2020-2024\/"},"author":{"name":"adm-fhuc2-la","@id":"https:\/\/fhucare.com\/fr\/#\/schema\/person\/2e9ff2878c5ffade65bdda120c97b8e0"},"headline":"MAIN ACHIEVEMENTS &amp; SIGNIFICANT ACTIONS 2020-2024","datePublished":"2024-07-19T14:05:36+00:00","dateModified":"2025-12-25T18:00:48+00:00","mainEntityOfPage":{"@id":"https:\/\/fhucare.com\/fr\/event\/main-achievements-significant-actions-2020-2024\/"},"wordCount":396,"publisher":{"@id":"https:\/\/fhucare.com\/fr\/#organization"},"image":{"@id":"https:\/\/fhucare.com\/fr\/event\/main-achievements-significant-actions-2020-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/fhucare.com\/wp-content\/uploads\/2024\/07\/LOGO-H-FHU-CARE-MULTICOLOR.png","articleSection":["Event"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/fhucare.com\/fr\/event\/main-achievements-significant-actions-2020-2024\/","url":"https:\/\/fhucare.com\/fr\/event\/main-achievements-significant-actions-2020-2024\/","name":"MAIN ACHIEVEMENTS &amp; SIGNIFICANT ACTIONS 2020-2024 - FHU CARE\u00b2","isPartOf":{"@id":"https:\/\/fhucare.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fhucare.com\/fr\/event\/main-achievements-significant-actions-2020-2024\/#primaryimage"},"image":{"@id":"https:\/\/fhucare.com\/fr\/event\/main-achievements-significant-actions-2020-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/fhucare.com\/wp-content\/uploads\/2024\/07\/LOGO-H-FHU-CARE-MULTICOLOR.png","datePublished":"2024-07-19T14:05:36+00:00","dateModified":"2025-12-25T18:00:48+00:00","breadcrumb":{"@id":"https:\/\/fhucare.com\/fr\/event\/main-achievements-significant-actions-2020-2024\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fhucare.com\/fr\/event\/main-achievements-significant-actions-2020-2024\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/fhucare.com\/fr\/event\/main-achievements-significant-actions-2020-2024\/#primaryimage","url":"https:\/\/fhucare.com\/wp-content\/uploads\/2024\/07\/LOGO-H-FHU-CARE-MULTICOLOR.png","contentUrl":"https:\/\/fhucare.com\/wp-content\/uploads\/2024\/07\/LOGO-H-FHU-CARE-MULTICOLOR.png","width":554,"height":176},{"@type":"BreadcrumbList","@id":"https:\/\/fhucare.com\/fr\/event\/main-achievements-significant-actions-2020-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/fhucare.com\/fr\/"},{"@type":"ListItem","position":2,"name":"MAIN ACHIEVEMENTS &amp; SIGNIFICANT ACTIONS 2020-2024"}]},{"@type":"WebSite","@id":"https:\/\/fhucare.com\/fr\/#website","url":"https:\/\/fhucare.com\/fr\/","name":"FHU CARE\u00b2","description":"Innovations in Autoimmunity, Cancer &amp; Immunotherapies","publisher":{"@id":"https:\/\/fhucare.com\/fr\/#organization"},"alternateName":"CARE2","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fhucare.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/fhucare.com\/fr\/#organization","name":"FHU CARE\u00b2","alternateName":"CARE2","url":"https:\/\/fhucare.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/fhucare.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/fhucare.com\/wp-content\/uploads\/2025\/11\/CARE2-COULEUR.svg","contentUrl":"https:\/\/fhucare.com\/wp-content\/uploads\/2025\/11\/CARE2-COULEUR.svg","caption":"FHU CARE\u00b2"},"image":{"@id":"https:\/\/fhucare.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/in\/fhucare\/","https:\/\/www.youtube.com\/@fhucare\/"]},{"@type":"Person","@id":"https:\/\/fhucare.com\/fr\/#\/schema\/person\/2e9ff2878c5ffade65bdda120c97b8e0","name":"adm-fhuc2-la","sameAs":["https:\/\/fhucare.com"]}]}},"_links":{"self":[{"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/posts\/1366","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/comments?post=1366"}],"version-history":[{"count":2,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/posts\/1366\/revisions"}],"predecessor-version":[{"id":2395,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/posts\/1366\/revisions\/2395"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/media\/1367"}],"wp:attachment":[{"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/media?parent=1366"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/categories?post=1366"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fhucare.com\/fr\/wp-json\/wp\/v2\/tags?post=1366"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}